FDA approves ZITUVIMET by Zydus Lifesciences for Type 2 diabetes treatment

Pallavi Madhiraju- November 6, 2023 0

Zydus Lifesciences Limited has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for ZITUVIMET, a combination of Sitagliptin and ... Read More

Lupin acquires diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim

Pallavi Madhiraju- August 19, 2023 0

In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ... Read More

Dr. Reddy’s Laboratories debuts generic version of KOMBIGLYZE XR in US

Pallavi Madhiraju- August 13, 2023 0

In a significant development for diabetes treatment in the U.S., Dr. Reddy's Laboratories has unveiled its Saxagliptin and Metformin Hydrochloride Extended-Release Tablets. This launch introduces ... Read More

BRENZAVVY proves effective in TheracosBio’s Phase 3 Type 2 diabetes study

Pallavi Madhiraju- August 4, 2023 0

TheracosBio announced the publication of a 24-week randomized, double-blind, placebo-controlled trial, proving Bexagliflozin's effectiveness as an adjunct to Metformin for treating adults with type 2 ... Read More

Zydus Lifesciences gets FDA tentative approval for Invokamet generic

Pallavi Madhiraju- February 22, 2023 0

Zydus Lifesciences said that its subsidiary Zydus Pharmaceuticals (USA) has been granted tentative approval for Canagliflozin and Metformin Hydrochloride Tablets, 50mg/500mg, 50mg/1,000mg, 150mg/500mg, and 150mg/1,000mg ... Read More

AstraZeneca India scraps Dapagliflozin distribution deal with Abbott

pallavi123- May 30, 2021 0

AstraZeneca Pharma India (AstraZeneca India) said that it has scrapped its distribution agreement with Abbott Healthcare pertaining to its Type 2 diabetes drug Dapagliflozin in ... Read More